Innovation of Diagnosis and Treatment for Pancreatic Cancer, Softcover reprint of the original 1st ed. 2017

This collection of chapters describes in detail the latest insights into the evaluation of resectability and neoadjuvant therapy to pancreaticoduodenectomy and distal pancreatectomy for pancreatic cancer. Shedding light on immunotherapy and gene therapy, this volume comprehensively covers treatments and procedures for the disease, allowing surgeons and trainees to gain an overview and explore innovative treatments. It also provides information on various cases using tools such as endoscopic ultrasound, MDCT, PET for diagnosis and laparoscopy and robotic resection methods. 

Edited and authored by pioneering professionals, Diagnosis and Treatment for Pancreatic Cancer is a valuable resource for gastroenterologists, medical oncologists, surgical oncologist and general surgeons interested in treatment of pancreatic cancer care.

Part1: Diagnosis of Pancreatic Cancer

1 Early diagnosis for pancreatic cancer using endoscopic ultrasound

2 Evaluation of resectability for pancreatic cancer using endoscopic ultrasound

3 Evaluation of resectability for pancreatic cancer by MDCT before and after neoadjuvant therapy

4 Evaluation of effect of neoadjuvant therapy using positron emission tomography

5 Liquid biopsy for early diagnosis of pancreatic cancer

Part 2: The Indication and Procedure of Pancreaticoduodenectomy for Pancreatic Cancer

6 Panceraticoduodenectomy- standard resection and extended resection-

7 

8 Pancreaticoduodenectomy with portal vein resection

9 Pancreaticoduodenectomy with main vascular resection

10 Laparoscopic pancreaticoduodenectomy

11 Robotic pancreaticoduodenectomy

Part 3: The Indication and Procedure of Distal Pancreatectomy

12 Distal pancreatectomy for pancreatic carcinoma

13 Distal pancreatectomy with celiac axis en-bloc resection (DP-CAR) for pancreatic carcinoma

14 Modified DP-CAR for pancreatic carcinoma

15 Laparoscopic distal pancreatectomy

16 Development of Cancer Vaccine and Targeted Immune Checkpoint Thera

17 Development of Hypoxia-activated, cytotoxic prodrug 

Second Department Surgery, Wakayama Medical University